{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-060879","form_type":"8-K","ticker":"PFSA","cik":"0001859807","company_name":"Profusa, Inc.","filed_at":"2026-05-26T15:05:14+00:00","discovered_at":"2026-05-26T15:06:00.393384+00:00","generated_at":"2026-05-26T15:07:00.627884+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"confidence":"high","headline":"Profusa and Bio Insights amend asset purchase agreement; delete provision for 12% management share issuance","bullets":["Amendment removes Section 4.6 requiring issuance of 12% fully diluted shares to CEO and CFO as retention.","$30M purchase price for PanOmics multi-omics assay know-how, paid in Series A Convertible Preferred, unchanged.","Amendment confirms no other changes to the Asset Purchase Agreement remain in full force."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060879","json":"https://secwatch.observer/filing/0001213900-26-060879.json","markdown":"https://secwatch.observer/filing/0001213900-26-060879.md","text":"https://secwatch.observer/filing/0001213900-26-060879.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859807/000121390026060879/0001213900-26-060879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859807/000121390026060879/ea0292151-8k_profusa.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T15:07:00.627884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}